Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;16(13):e1905614.
doi: 10.1002/smll.201905614. Epub 2020 Mar 5.

Tracking Drug-Induced Epithelial-Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay

Zhen Zhang  1 , Jing Wang  1 , Karthik Balaji Shanmugasundaram  1 , Belinda Yeo  2 , Andreas Möller  3 , Alain Wuethrich  1 , Lynlee L Lin  1   4 , Matt Trau  1   5
Affiliations

Tracking Drug-Induced Epithelial-Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay

Zhen Zhang et al. Small. 2020 Apr.

Abstract

Epithelial-mesenchymal transition (EMT) is a primary mechanism for cancer metastasis. Detecting the activation of EMT can potentially convey signs of metastasis to guide treatment management and improve patient survival. One of the classic signatures of EMT is characterized by dynamic changes in cellular expression levels of E-cadherin and N-cadherin, whose soluble active fragments have recently been reported to be biomarkers for cancer diagnosis and prognosis. Herein, a microfluidic immunoassay (termed "SERS immunoassay") based on sensitive and simultaneous detection of soluble E-cadherin (sE-cadherin) and soluble N-cadherin (sN-cadherin) for EMT monitoring in patients' plasma is presented. The SERS immunoassay integrates in situ nanomixing and surface-enhanced Raman scattering readout to enable accurate detection of sE-cadherin and sN-cadherin from as low as 10 cells mL-1 . This assay enables tracking of a concurrent decrease in sE-cadherin and increase in sN-cadherin in breast cancer cells undergoing drug-induced mesenchymal transformation. The clinical potential of the SERS immunoassay is further demonstrated by successful detection of sE-cadherin and sN-cadherin in metastatic stage IV breast cancer patient plasma samples. The SERS immunoassay can potentially sense the activation of EMT to provide early indications of cancer invasions or metastasis.

Keywords: SERS immunoassays; breast cancer; cancer metastasis; epithelial-mesenchymal transition; nanoparticles; soluble proteins.

PubMed Disclaimer

References

    1. a) T. N. Seyfried, L. C. Huysentruyt, Crit. Rev. Oncog. 2013, 18, 43;
    1. b) S. Heerboth, G. Housman, M. Leary, M. Longacre, S. Byler, K. Lapinska, A. Willbanks, S. Sarkar, Clin. Transl. Med. 2015, 4, 6.
    1. a) O. J. Scully, B. H. Bay, G. Yip, Y. Yu, Cancer Genomics Proteomics 2012, 9, 311;
    1. b) M. E. Menezes, S. K. Das, I. Minn, L. Emdad, X. Y. Wang, D. Sarkar, M. G. Pomper, P. B. Fisher, Adv. Cancer Res. 2016, 132, 1.
    1. A. F. Hottinger, A. Hormigo, in Encyclopedia of Cancer (Ed: M. Schwab), Springer, Berlin 2011, p. 3390.

Publication types

LinkOut - more resources